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Abstract 
Background: In the ANRS EASIER trial where treatment‑experienced patients switched from enfuvirtide (ENF) to 
raltegravir (RAL), a high incidence of transaminase elevation was reported in the RAL arm.
Methods: We compared the incidence of emergent liver enzyme elevations (LEE) of grade 2 or more among patients 
randomized to the maintenance ENF arm or the switch RAL arm up to W24. We also assessed the overall incidence of 
LEE over the 48‑week duration of the trial and baseline risk factors for grade 2 or more alanine aminotransferase (ALT) 
elevation using univariate and multivariate analyses.
Results: During the first 24 weeks, 6/84 (7.1 %) and 2/85 patients (2.4 %) presented with ALT elevation of grade 2 or 
more in the RAL and ENF arms, respectively (p = 0.21). Grade 2 or more γGT and ALP elevations were seen in 18 and 
11 % (p = 0.35), and 5 and 1 % (p = 0.14) of patients in the RAL and ENF arms, respectively. The 48‑week incidence 
of grade 2 or more LEE was 11.6 per 100‑pts‑years for ALT, 24.5 per 100‑pts‑years for γ‑GT and 4.5 per 100‑pts‑years 
for ALP, respectively. In the multivariate analysis, tipranavir/ritonavir use (OR 3.66; 95 % CI [1.20–11.1], p = 0.022) and 
elevated ALT at baseline (OR 10.3; 95 % CI [2.67–39.6], p < 10−3) were significantly associated with a grade 2 or more 
ALT elevation during follow‑up.
Conclusion: The incidence of LEE was relatively high in these highly treatment‑experienced patients switching to a 
RAL‑based regimen. Both tipranavir/ritonavir use and high baseline ALT levels were associated with an increased risk 
of ALT.
Trial registration: ClinicalTrials.gov identifier: NCT00454337
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Background
Liver enzyme elevations (LEE) and in particular alanine 
aminotransferase (ALT) elevations are frequently reported 
in patients receiving antiretroviral therapy (ART), 
although severe ALT elevations (grade 3 or more) are only 
seen in 2–10 % of patients and do not usually require drug 
discontinuation [1–3]. Such LEE occur more frequently 
in patients with underlying liver disease, such as HCV or 
HBV co-infection and in ART-experienced as compared 
to ART-naïve patients [1–3]. Different from ritonavir 
boosted protease inhibitors (PIs/r) and non-nucleoside 
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reverse transcriptase inhibitors (NNRTIs), the liver safety 
profile of integrase inhibitors and raltegravir (RAL) in 
particular appears favourable [4]. Indeed, in treatment-
experienced patients receiving RAL or placebo in addi-
tion to an optimized background regimen (BR), a similar 
incidence of grade 3–4 ALT elevation was seen at week 
48 (4.3 vs 3.4  %) and week 96 (5.4 vs 4.2  %) in the RAL 
and placebo arms, respectively [5, 6]. As expected, ALT 
elevations were more frequent in HBV/HCV co-infected 
patients [4–7]. Also, in another randomized trial among 
treatment experienced patients, only 2 % of patients who 
started RAL in addition to the optimized BR experienced 
a grade 3–4 ALT elevation at week 48, as compared to 3 % 
for those starting dolutegravir, although 16 % of patients 
were HBV and/or HCV co-infected [8]. We were there-
fore surprised observe a higher incidence of LEE in the 
EASIER ANRS 138 trial in which highly treatment-experi-
enced patients switched from enfuvirtide to RAL in addi-
tion to the maintenance of their BR [9]. Indeed, during the 
first 24 weeks of this trial 21 % of patients in the RAL arm 
experienced ALT elevations of grade 1 or more. Of note 
2 patients experienced a grade 4 ALT elevation requiring 
raltegravir discontinuation. Both patients were receiving a 
tipranavir and RAL could be resumed once tipranavir was 
switched for darunavir [9]. We therefore wished to assess 
the incidence of LEE in this study and analyze risk factors 
associated with ALT elevations, including the potential 
role of tipranavir.
Methods
ANRS 138‑EASIER trial population
The EASIER ANRS 138 trial was a prospective, multi-
center, randomized, 48-week, open-label non-inferiority 
trial that compared an immediate to a deferred (at week 
24) switch from enfuvirtide (ENF) to RAL in highly treat-
ment-experienced HIV-infected patients. A total of 169 
patients were enrolled in the study, results have been pre-
viously published and showed the non-inferiority of RAL 
vs ENF [9, 10]. Briefly, eligible patients were integrase 
inhibitor naïve HIV-1 infected adults with a history of 
triple class [PI, nucleoside reverse-transcriptase inhibitor 
(NRTI), and non- nucleoside reverse-transcriptase inhib-
itor (NNRTI)] failure or intolerance who had achieved 
virologic suppression with an ENF- based regimen, with 
plasma HIV-1 RNA levels  <400 copies/mL and stable 
ART for at least 3 months.
Liver enzymes monitoring
To be enrolled in the study patients had to have ALT lev-
els of less than 2.5 times the upper limit of normal (ULN) 
(grade 0–1). There were no inclusion criteria relative to 
alkaline phosphatase (ALP) or γ-glutamyl transferase 
(γ-GT) levels. LEE was defined by any emergent grade 2, 
3 or 4 elevation of either ALT, ALP or γ-GT from baseline 
to W24 for comparative study (RAL vs ENF) or to W48 
for the observational study since all patients in the ENF 
arm switched to RAL at week 24. Patients were assessed 
for liver enzyme at baseline, weeks 2, 4, 8, 16, 24 (26 in 
those switching to RAL at week 24), 28, 32, 40, and 48. 
Laboratory abnormalities were graded according to the 
ANRS grading scale for adverse events in adults (http://
www.anrs.fr/index.php/content/download/2250/12981/
file/ANRS-GradeEI-V6-Fr-2003.pdf). According to this 
grading scale, a grade 2 elevation of LEE was defined as 
2.5–5 times the ULN, a grade 3 as 5–10 times the ULN, 
and a grade 4 elevation as more than 10 times the ULN.
Study objectives and statistical analysis
The first objective of this study was to estimate the inci-
dence of emergent grade 2 or more LEE (ALT, ALP, 
γ-GT) during the study period. The primary compara-
tive intent-to-treat analysis, included all data available up 
to week 24, and compared the RAL and the ENF arms. 
A longitudinal analysis was then performed considering 
all data up to week 48 for all patients. Indeed, from week 
24 all patients were receiving a RAL-based regimen. Chi 
square or Fisher exact tests were used to compare quali-
tative variables. Kaplan-Meir plots were performed to 
represent the time to the occurrence of LEE.
The secondary objective of the study was to identify 
baseline risk factors for emerging ALT elevation of grade 
2 or more. A univariate logistic regression model was 
used, including the following variables: treatment group 
(RAL vs ENF), age, sex, body mass index (BMI), CD4 cell 
count, ART duration, history of drug abuse, use of ritona-
vir boosted tipranavir, ALT elevation at baseline (grade 1 
or more), alcohol use, HBV or HCV co-infection, under-
lying liver disease (liver cirrhosis or steatosis), and use of 
lipid lowering agents. All variables with a p value below 
0.10 were then included in a multivariate model with the 
addition of alcohol use and underlying liver disease.
Comparisons were made with use of a 2-sided alpha level 
of 0.05. Statistical analyses were performed with the use of 
SAS software version 9.2 (SAS Institute Inc, Cary, NC).
Results
Characteristics of the patients enrolled in the ANRS‑138 
EASIER trial
Between June 2007 and September 2007, 170 patients 
were randomized into the study. One patient withdrew 
consent before W0 and was therefore excluded from the 
analysis. The baseline characteristics of the remaining 169 
patients were well balanced between both arms (Table 1). 
Overall, 168 patients (99 %) completed 48 weeks of fol-
low-up. Patients were mostly men (85 %), with a median 
age of 48 years, and were heavily treatment-experienced 
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with a median duration of ART of 13.6  years and a 
median duration of ENF of 2.3  years before randomi-
zation. Treatment regimen at baseline included ENF 
(100 %), at least one NRTI (95 %), one or two PIs (99 %), 
and one NNRTI (8 %). Among the 83 patients of the RAL 
arm receiving a PI, 37 (44 %) were on TPV and 30 (36 %) 
were on darunavir (DRV) and among the 85 patients of 
the ENF arm receiving a PI, 29 (34 %) were on TPV and 
34 (40 %) were on darunavir (DRV).
Incidence of liver enzyme elevations
At baseline, 8–10 % of patients in both arms had grade 1 
ALT, and only 2 patients, one in each arm had a grade 2 
or 3 ALT elevation (Table 1). Grade 2 or more γ-GT ele-
vations were seen at baseline in 19 and 12 % of patients in 
the RAL and ENF arms, respectively. Only one patient in 
the RAL arm had a grade 2 ALP elevation.
During the first 24  weeks of the study, numerically 
more grade 2 or higher LEE were seen in the RAL arm 
but the difference did not reach significance (tests 
adjusted on tipranavir use in BR): 8 grade 2 or more ALT 
elevations [6 in the RAL arm (7.1 %) and 2 (2.4 %) in the 
ENF arm, p = 0.21], 24 grade 2 or more γ-GT elevations 
[15 (18 %) in the RAL arm and 9 (11 %) in the ENF arm, 
p = 0.35] and 5 grade 2 or more PAL elevations [4 (5 %) 
in the RAL arm and 1 (1 %) in the ENF arm, p = 0.14].
In the observational analysis considering all patients 
up to week 48, whether or not on RAL, grade 2 or more 
LEE were distributed as follows: 18 ALT elevations (9 
grade 2, 9 grade 3–4) corresponding to an overall inci-
dence of 11.6 events per 100-patients-year (Fig.  1), and 
to a grade 3–4 incidence of 5.8 events per 100-patients-
year, 38 γ-GT elevations (28 grade 2, 10 grade 3–4) corre-
sponding to an incidence of 24.5 events per 100 pts-year 
and 7 PAL (5 grade 2, 2 grade 3–4) corresponding to an 
incidence of 4.5 events per 100 pts-year. Among the 9 
patients with grade 3–4 ALT elevations, tipranavir was 
Table 1 Baseline characteristics of  the patients enrolled 
in the ANRS 138 EASIER trial
Characteristic RAL arm ENF arm
(n = 84) (n = 85)
Age (years)
 Median 47.6 48.4
 Interquartile range 43.0; 53.7 44.0; 54.3
Male sex, no. (%) 70 (83) 73 (86)
Route of HIV infection, no. (%)
 Sexual 73 (87) 74 (87)
 Injection‑drug use 5 (6) 5 (6)
 Other or unknown 6 (7) 6 (7)
CDC stage, no. (%)
 A 16 (19) 14 (16)
 B 26 (31) 24 (28)
 C 42 (50) 47 (55)
History of viral hepatitis co‑infection
 HBs Ag positive 1 (1) 0 (0)
 HCV RNA positive 6 (7) 4 (5)
Cirrhosis 0 (0) 0 (0)
Non alcoolic fatty liver disease 9 (11) 5 (6)
Alcohol consumption
 ≥3 times per week 11 (13) 19 (22)
ALAT levels at baseline
 Grade 0 75 (89) 76 (89)
 Grade 1 8 (10) 7 (8)
 Grade 2 0 (0) 1 (1)
 Grade 3 1 (1) 0 (0)
 Grade 4 0 (0) 0(0)
Body mass index (BMI)
 Median 22.3 22.6
 Interquartile range 19.9; 24.0 20.6; 24.8
Baseline CD4 cells per μL
 Median 410 374
 Interquartile range 259; 505 277; 535
Plasma HIV RNA < 50 cp/mL, no. (%) 71 (85) 75 (88)
Duration of prior antiretroviral therapy (years)
 Median 13.7 13.6
 Interquartile range 12.1; 15.0 11.7; 15.4
Duration of prior enfuvirtide therapy (years)
 Median 2.5 2.2
 Interquartile range 1.6; 3.5 1.4; 3.4
Number of antiretroviral drugs in baseline regimen (including enfuvir‑
tide)
 Median 4 4
 Interquartile range 4; 5 4; 5
Antiretroviral drugs in baseline regimen (apart from enfuvirtide)
 Protease inhibitors, no. (%) 83 (99) 85 (100)
  Tipranavir/ritonavir 37 (44) 29 (34)
  Darunavir/ritonavir 30 (36) 34 (40)
  Atazanavir/ritonavir 2 (2) 2 (2)
  Lopinavir/ritonavir 9 (11) 15 (18)
Table 1 continued
Characteristic RAL arm ENF arm
(n = 84) (n = 85)
  Fosamprenavir/ritonavir 11 (13) 11 (13)
 NRTIs, no. (%) 79 (94) 81 (95)
  Tenofovir 50 (60) 46 (54)
  Lamivudine 36 (43) 32 (38)
  Emtricitabine 26 (31) 28 (33)
  Abacavir 31 (37) 29 (34)
 NNRTIs, no. (%) 8 (10) 5 (6)
  Nevirapine 5 (6) 1 (1)
  Efavirenz 3 (4) 3 (4)
  Etravirine 0 (0) 1 (1)
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replaced by either darunavir (n = 8) or lopinavir (n = 1) 
and RAL could be resumed in the 3 patients (all in the 
RAL arm) in whom it was temporarily discontinued. Of 
note, among the 11 patients (6.5 %) who were HBV (HBs 
Ag positive) or HCV (HCV RNA positive) co-infected in 
this trial, only one patient with HCV co-infection experi-
enced a grade 2 ALT elevation.
Risk factors for ALT elevation
In order to identify baseline risk factors of emergent 
grade 2 or more ALT elevation we first performed a uni-
variate logistic regression model. Among all baseline 
variables tested, two were significantly associated with 
emergent grade 2 or more ALT elevation (Table 2): ele-
vated ALT (grade 1 or more) with an OR of 8.78 (95 % CI 
[2.80–27.6], p  <  10−3) and tipranavir use in BR with an 
OR of 3.56 (95 % CI [1.26–10.0], p = 0.016). In the multi-
variate analysis, these two factors remained significantly 
associated with the occurrence of emergent ALT eleva-
tion of grade 2 or more (Table 2).
Discussion
In this trial among treatment-experienced patients viro-
logically suppressed under an ENF-based regimen com-
bining ritonavir boosted PIs and NRTIs, the switch from 
ENF to RAL to avoid parenteral injections of ENF, was 
not associated with a significant increase in LEE. Indeed, 
during the first 24  weeks of this randomized trial, only 
6/84 (7.1 %) and 2/85 patients (2.4 %) presented with ALT 
elevations of grade 2 or more in the RAL and ENF arms, 
respectively (p = 0.21). Also, the frequencies of grade 2 
or more ALT and γ-GT elevations were not significantly 
higher in the RAL as compared to the ENF arm. However, 
the 48-week incidence of grade 2 or more ALT elevation 
was 11.6 per 100-pts-years in this study, and that of grade 
3 or 4 ALT elevation was 5.8 per 100-pts-years, an inci-
dence somewhat higher than previously reported at W48 
in treatment-experienced patients receiving RAL-based 
regimens: 4.3 % in the BENCHMRK study and 2 % in the 
SAILING study [5–8].
To better understand this observation we performed 
a multivariate analysis, to identify the baseline risk fac-
tors associated with a new grade 2 or more ALT eleva-
tion during the 48-week duration of the study (Table 2). 
Two baseline variables were significantly associated with 
such an ALT elevation: tipranavir/ritonavir use in the BR 
(OR 3.66; 95  % CI [1.20–11.1], p =  0.022) and elevated 
ALT at baseline (grade 1 and more) (OR 10.3; 95  % CI 
[2.67–39.6], p  <  10−3) whereas the use of RAL was not 
significantly associated to such an emergent increase in 
ALT levels.
These results might therefore explain the relatively high 
incidence of LEE in this trial. Indeed tipranavir use has 
been previously associated with a high incidence of ALT 
elevations in particular among HCV or HBV co-infected 
patients, possibly also because of the double dose of rito-
navir (200 mg bid) used to boost tipranavir as compared 
to only 100 mg bid for most of the other PIs (darunavir 
and lopinavir) [11]. Also, in pooled safety analyses from 
phase II and III tipranavir/ritonavir development trials, 
during the 96 weeks follow-up of 1299 patients receiving 
Fig. 1 Kaplan‑Meier survival probability without grade 2 or more ALT 
elevation according to the use of tipranavir (TPV) in baseline regimen 
(BR)
Table 2 Univariate and  multivariate analysis of  baseline 
risk factors associated with grade 2 or more ALT elevation
Odds ratio 95 % CI p value
Univariate analysis
 Raltegravir vs enfuvirtide 1.66 (0.61–4.51) 0.322
 Age (↑ 10 years) 1.12 (0.62–2.05) 0.702
 Sex (female/male) 2.36 (0.76–7.31) 0.136
 Body mass index (BMI) (↑ 5) 0.73 (0.31–1.70) 0.469
 CD4 cell count (↑ 100 cells/µL) 1.08 (0.87–1.34) 0.502
 ART duration (↑ 1 year) 0.86 (0.70–1.05) 0.149
 History of drug abuse 0.92 (0.11–7.73) 0.940
 Use of boosted tipranavir at 
baseline
3.56 (1.26–10.0) 0.016
 ALT elevation (grade 1 or more) 8.78 (2.80–27.6) <10−3
 Alcohol use (>2 times/week) 0.54 (0.12–2.51) 0.435
 Hepatitis B or C co‑infection 0.82 (0.10–6.84) 0.857
 Liver disease at baseline (steatosis/
cirrhosis)
2.53 (0.63–10.1) 0.189
 Use of lipid lowering agents 2.06 (0.76–5.57) 0.156
Multivariate analysis
 Use of boosted tipranavir 3.66 (1.20–11.1) 0.022
 ALT elevation (grade 1 or more) 10.3 (2.67–39.6) <10−3
 Alcohol use (>2 times/week) 0.39 (0.07–2.16) 0.281
 Liver disease at baseline (steatosis/
cirrhosis)
0.89 (0.16–5.01) 0.899
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tipranavir/ritonavir, 11 % of patients experienced a grade 
3–4 ALT elevation [12]. In our trial a sizeable propor-
tion of patients (66/168; 39 %) were receiving tipranavir 
at baseline, slightly more in the RAL (44 %) than in the 
ENF (34 %) arm. In other trials of treatment experienced 
patients starting RAL in combination with a boosted PI, 
lower proportion of patients were receiving tipranavir/
ritonavir, only 22 % of patients in the Benchmrk trial, less 
than 20 % in the Sailing trial and 0 % in the ANRS TRIO 
trial, and this may account for the differences seen in the 
incidence of LEE elevations across these trials [5–7, 13].
Close monitoring of LEE and ALT elevation in particu-
lar is recommended when patients are receiving ritonavir 
boosted-tipranavir, and in case of significant ALT eleva-
tion a switch to a more liver-friendly PIs such as daruna-
vir or lopinavir could be tested. Indeed, in the 9 patients 
who discontinued RAL because of grade 3–4 ALT eleva-
tions during our study, all under a ritonavir/tipranavir-
based regimen, RAL could be resumed in combination 
with a new boosted PI. RAL would also be unlikely to 
increase tipranavir liver toxicity since a previous phar-
macokinetic sub-study of the ANRS EASIER trial showed 
that the switch from ENF to RAL lowered plasma con-
centrations of tipranavir [14]. Elevated ALT at baseline 
was also identified as a risk factor for the occurrence 
of a new ALT elevation during follow-up as previously 
reported [15]. Close monitoring of ALT levels should also 
be performed in such patients.
Conclusion
Among highly treatment experienced patients RAL is 
not associated per se with an increase in LEE but liver 
enzymes and ALT should be carefully monitored in 
patients receiving a tipranavir-based regimen or with ele-
vated baseline ALT levels.
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